Development of a Nanoemulsion Adjuvant: HIV elective project

纳米乳剂佐剂的开发：艾滋病毒选修项目

• 批准号: 9263735
• 负责人: Ali I. Fattom
• 金额: $ 238.15万
• 依托单位: BLUEWILLOW BIOLOGICS, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2017-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9263735
• 关键词: Adjuvant; Development; Emerging Communicable Diseases; HIV; Human; Infection; Lead; Licensing; Licensure; National Institute of Allergy and Infectious Disease; Program Development; Vaccine Adjuvant; Vaccines; nanoemulsion; pathogen

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants through immunological characterization studies and lead compound optimization, up to and including IND-enabling studies, all towards licensure for human use. Adjuvants will be studied with currently licensed or new investigational vaccines to protect against infection by NIAID emerging and re-emerging infectious disease pathogens.

NIAID/DAIT 佐剂开发计划通过免疫学表征研究和先导化合物优化，直至并包括 IND 启用研究，支持新候选疫苗佐剂的开发，所有这些都是为了获得人类使用许可。佐剂将与目前获得许可的或新的研究疫苗一起进行研究，以防止 NIAID 新出现和重新出现的传染病病原体的感染。